Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines

To counter the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), some have proposed accelerating SARS-CoV-2 vaccine development through controlled human infection (or ‘challenge’) trials. These trials would involve the deliberate exposure of relatively few young, healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Steel, Robert, Buchak, Lara, Eyal, Nir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Current Controversy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371490/
https://www.ncbi.nlm.nih.gov/pubmed/32661074
http://dx.doi.org/10.1136/medethics-2020-106501
Descripción
Sumario:To counter the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), some have proposed accelerating SARS-CoV-2 vaccine development through controlled human infection (or ‘challenge’) trials. These trials would involve the deliberate exposure of relatively few young, healthy volunteers to SARS-CoV-2. We defend this proposal against the charge that there is still too much uncertainty surrounding the risks of COVID-19 to responsibly run such a trial.

Ejemplares similares